A new article in the peer-reviewed journal Nucleic Acid Therapeutics describes the characterization of antibodies targeting antisense oligonucleotide (ASO) phosphorothioate and 2'-methoxyehtyl modifications for intracellular trafficking and biodistribution studies. Click here to read the article.
Peter Oliver and Xiao Wan, from the Research Complex at Harwell, U.K., and coauthors, validated new panels of antibody reagents that target clinically relevant nucleic acid modifications for visualizing ASOs both in vitro and in vivo. The investigators tested ASOs in vitro for intracellular localization by immunocytochemistry and for biodistribution in mouse tissues by immunohistochemistry.
"Our data demonstrate the utility of these reagents for the NAT field, where modified nucleic acids can be detected irrespective of the nucleotide sequence, rendering the system amenable for multiple clinical and pre-clinical workflows and quantitative immunoassays," stated the investigators.
"Advancing expedited preclinical development requires better tools to trace the biodistribution of potential oligonucleotide therapeutics in vivo to bring them to the clinical arena," says Executive Editor Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Children's Hospital of Michigan, Detroit, MI.
About the Journal
Nucleic Acid Therapeutics is an authoritative peer-reviewed journal published bimonthly in print and online that focuses on cutting-edge basic research, therapeutic applications, and drug development using nucleic acids or related compounds to alter gene expression. The Journal is under the editorial leadership of Co-Editors-in-Chief Bruce A. Sullenger, PhD, Duke Translational Research Institute, Duke University Medical Center and Annemieke Aartsma-Rus, PhD, Leiden University Medical Center, and Executive Editor Graham C. Parker, PhD. Nucleic Acid Therapeutics is the official journal of the Oligonucleotide Therapeutics Society . Complete tables of content and a sample issue may be viewed on the Nucleic Acid Therapeutics website.
About the Society
The Oligonucleotide Therapeutics Society is an open, non-profit forum to foster academia- and industry-based research and development of oligonucleotide therapeutics. The society brings together the expertise from different angles of oligonucleotide research to create synergies and to bring the field of oligonucleotides to its full therapeutic potential.
About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.
